I am a
Home I AM A Search Login

Papers of the Week

2022 Dec




Tocilizumab-Induced Dermatosis in a Patient With Rheumatoid Arthritis.


Babkoor D, Alshuqayfi A, Alshegaifi N, Bamosa H, Alsaid M, Alkinani A, Algozi S, AlZaidi R, Alahmadi L, Hafiz WA
Cureus. 2022 Dec; 14(12):e32967.
PMID: 36712740.


Rheumatoid arthritis is a chronic systemic autoimmune disease that results in symmetrical inflammatory polyarthritis with extra-articular involvement, including skin manifestations. It targets the lining of the synovial membranes and is treated with disease-modifying antirheumatic drugs. If left untreated, it leads to increased morbidity, mortality, and socioeconomic burdens. Tocilizumab is a humanized monoclonal antibody that binds to interleukin-6 receptors and is used to treat rheumatoid arthritis in patients with inadequate response to conventional synthetic therapy. This medication can cause adverse dermatologic events, such as urticaria, pruritus, and mild maculopapular rash. In this case, we report a 39-year-old woman with rheumatoid arthritis who developed tocilizumab-induced dermatosis.